Kymera Therapeutics (NASDAQ:KYMR) Trading Down 6.2% – Should You Sell?

Kymera Therapeutics, Inc. (NASDAQ:KYMR) dropped 6.2% on Tuesday . The company traded as low as $31.70 and last traded at $31.61. Approximately 160,447 shares changed hands during trading, a decline of 69% from the average daily volume of 513,364 shares. The stock had previously closed at $33.70.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on KYMR shares. HC Wainwright raised their price objective on Kymera Therapeutics from $54.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, February 28th. BMO Capital Markets started coverage on shares of Kymera Therapeutics in a research report on Friday, December 6th. They set a “market perform” rating and a $55.00 price objective on the stock. Citigroup initiated coverage on Kymera Therapeutics in a research note on Thursday, March 13th. They set a “buy” rating and a $52.00 price objective on the stock. Leerink Partners reiterated an “outperform” rating and issued a $60.00 price target on shares of Kymera Therapeutics in a report on Friday, December 27th. Finally, Stephens restated an “overweight” rating and issued a $60.00 target price on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. Three research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $56.36.

Kymera Therapeutics Stock Performance

The stock has a market capitalization of $2.07 billion, a price-to-earnings ratio of -13.60 and a beta of 2.22. The company has a 50-day moving average of $36.72 and a 200-day moving average of $42.18.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.12). Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The company had revenue of $7.39 million for the quarter, compared to analysts’ expectations of $14.81 million. As a group, analysts expect that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Insider Transactions at Kymera Therapeutics

In other news, COO Jeremy G. Chadwick sold 1,383 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $42,112.35. Following the completion of the transaction, the chief operating officer now directly owns 67,800 shares of the company’s stock, valued at approximately $2,064,510. This represents a 2.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Ellen Chiniara sold 3,129 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $41.75, for a total transaction of $130,635.75. Following the completion of the sale, the insider now directly owns 54,826 shares in the company, valued at approximately $2,288,985.50. This trade represents a 5.40 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 13,788 shares of company stock valued at $455,202. 15.82% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in KYMR. Blue Trust Inc. raised its stake in shares of Kymera Therapeutics by 74.8% in the 4th quarter. Blue Trust Inc. now owns 631 shares of the company’s stock worth $25,000 after buying an additional 270 shares in the last quarter. State of Wyoming purchased a new position in shares of Kymera Therapeutics during the fourth quarter valued at $45,000. GF Fund Management CO. LTD. acquired a new position in Kymera Therapeutics during the fourth quarter valued at $55,000. Quarry LP acquired a new stake in Kymera Therapeutics during the 3rd quarter worth about $95,000. Finally, KBC Group NV grew its stake in Kymera Therapeutics by 53.8% during the 4th quarter. KBC Group NV now owns 2,151 shares of the company’s stock valued at $87,000 after acquiring an additional 752 shares in the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.